CN104114152A - 用盐敏性乳液体系对人泪液膜进行有效脂质递送 - Google Patents

用盐敏性乳液体系对人泪液膜进行有效脂质递送 Download PDF

Info

Publication number
CN104114152A
CN104114152A CN201280067685.0A CN201280067685A CN104114152A CN 104114152 A CN104114152 A CN 104114152A CN 201280067685 A CN201280067685 A CN 201280067685A CN 104114152 A CN104114152 A CN 104114152A
Authority
CN
China
Prior art keywords
compositions
emulsion
xerophthalmia
treatment
nge
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280067685.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·G·维希格
P·A·西蒙斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47459152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104114152(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to CN201810890387.0A priority Critical patent/CN108969482A/zh
Publication of CN104114152A publication Critical patent/CN104114152A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280067685.0A 2011-12-07 2012-12-07 用盐敏性乳液体系对人泪液膜进行有效脂质递送 Pending CN104114152A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810890387.0A CN108969482A (zh) 2011-12-07 2012-12-07 用盐敏性乳液体系对人泪液膜进行有效脂质递送

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161568089P 2011-12-07 2011-12-07
US61/568,089 2011-12-07
US201261625401P 2012-04-17 2012-04-17
US61/625,401 2012-04-17
PCT/US2012/068615 WO2013086449A1 (en) 2011-12-07 2012-12-07 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810890387.0A Division CN108969482A (zh) 2011-12-07 2012-12-07 用盐敏性乳液体系对人泪液膜进行有效脂质递送

Publications (1)

Publication Number Publication Date
CN104114152A true CN104114152A (zh) 2014-10-22

Family

ID=47459152

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280067685.0A Pending CN104114152A (zh) 2011-12-07 2012-12-07 用盐敏性乳液体系对人泪液膜进行有效脂质递送
CN201810890387.0A Pending CN108969482A (zh) 2011-12-07 2012-12-07 用盐敏性乳液体系对人泪液膜进行有效脂质递送

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810890387.0A Pending CN108969482A (zh) 2011-12-07 2012-12-07 用盐敏性乳液体系对人泪液膜进行有效脂质递送

Country Status (27)

Country Link
US (2) US9314528B2 (enExample)
EP (5) EP3666257A1 (enExample)
JP (1) JP6142419B2 (enExample)
KR (1) KR102017922B1 (enExample)
CN (2) CN104114152A (enExample)
AR (1) AR089123A1 (enExample)
AU (2) AU2012347459A1 (enExample)
BR (1) BR112014013820A8 (enExample)
CA (1) CA2858574C (enExample)
CL (1) CL2014001518A1 (enExample)
CO (1) CO6990739A2 (enExample)
DK (2) DK2787968T3 (enExample)
ES (2) ES2797650T3 (enExample)
HU (2) HUE057140T2 (enExample)
IL (1) IL233008A (enExample)
IN (1) IN2014CN04809A (enExample)
MX (1) MX355216B (enExample)
MY (1) MY173378A (enExample)
PH (2) PH12014501296B1 (enExample)
PL (2) PL2787968T3 (enExample)
PT (2) PT2787969T (enExample)
RU (1) RU2014127074A (enExample)
SG (1) SG11201403013VA (enExample)
SI (2) SI2787969T1 (enExample)
TW (1) TWI652072B (enExample)
WO (2) WO2013086449A1 (enExample)
ZA (1) ZA201404228B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
DK3266446T3 (en) 2016-07-07 2019-02-11 Salvat Lab Sa Eye preparation comprising castor oil and medium chain triglyceride
EP3500344A4 (en) 2016-08-19 2020-08-05 Akrivista, LLC METHODS OF DIAGNOSIS AND TREATMENT OF DRY EYE SYNDROME AND COMPOSITIONS FOR TREATMENT OF A HUMAN EYE
CA3072494A1 (en) 2017-08-18 2019-02-21 Akrivista, LLC Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
TW202014194A (zh) 2018-04-27 2020-04-16 美商歐樂根公司 抗微生物功效增強且毒性降低之亞氯酸鈉組成物
WO2025175150A1 (en) * 2024-02-16 2025-08-21 Allergan, Inc. Enhanced artificial tear formulations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028110A2 (en) * 1979-10-26 1981-05-06 Smith and Nephew Associated Companies p.l.c. Autoclavable emulsions
CN101056618A (zh) * 2004-11-16 2007-10-17 阿勒根公司 眼用组合物和治疗眼睛的方法
WO2008106228A2 (en) * 2007-02-28 2008-09-04 Aciex Therapeutics, Inc. Methods and compositions for normalizing meibomian gland secretions
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
WO2010141648A2 (en) * 2009-06-05 2010-12-09 Allergan, Inc. Artificial tears and therapeutic uses

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IT1224795B (it) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
WO1991001718A1 (en) 1989-08-03 1991-02-21 Eisai Co., Ltd. Method of photostabilizing eyewash and photostabilized eyewash
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
CA2199610A1 (en) 1994-09-14 1996-03-21 Taisho Pharmaceutical Co., Ltd. Eye drops for repairing repairing corneal damage
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
DE69919379T2 (de) 1998-11-13 2005-09-08 Continental Projects Ltd. Komplexe von hyaluronic saure/carnitinen und pharmazeutische und kosmetische zusammensetzungen
JP2000159659A (ja) * 1998-11-30 2000-06-13 Kazuo Tsubota 眼科用人工涙液
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
JP2004503593A (ja) 2000-07-14 2004-02-05 アラーガン、インコーポレイテッド 増大した溶解度を持つ治療活性成分を含む組成物
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
CN1245166C (zh) 2000-11-08 2006-03-15 生物概念实验室 改进的含有单糖类作为防腐增强剂的眼科和隐形眼镜用溶液
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
EP1551399A4 (en) 2002-09-30 2011-01-05 Mark A Babizhayev METHOD FOR THE TOPICAL TREATMENT OF EYE DISEASES AND COMPOSITION AND DEVICE FOR THIS TREATMENT
AU2003301263A1 (en) * 2002-10-18 2004-05-04 Joel S. Echols Three layer tear formulation
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US6635654B1 (en) * 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
JPWO2004084877A1 (ja) 2003-03-26 2006-06-29 株式会社メニコン 眼科用組成物
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
KR101147046B1 (ko) * 2003-06-13 2012-05-22 알콘, 인코퍼레이티드 시너지성의 2개의 폴리머 배합물을 포함하는 안과용 조성물
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
WO2005046728A1 (ja) * 2003-11-10 2005-05-26 Toray Industries, Inc. 多糖類含有組成物および涙液層安定化点眼剤
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
JP4929245B2 (ja) 2008-07-31 2012-05-09 株式会社ベッセル工業 工具類のグリップ
WO2013049621A1 (en) * 2011-09-29 2013-04-04 The Board Of Regents Of The University Of Oklahoma Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028110A2 (en) * 1979-10-26 1981-05-06 Smith and Nephew Associated Companies p.l.c. Autoclavable emulsions
CN101056618A (zh) * 2004-11-16 2007-10-17 阿勒根公司 眼用组合物和治疗眼睛的方法
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
WO2008106228A2 (en) * 2007-02-28 2008-09-04 Aciex Therapeutics, Inc. Methods and compositions for normalizing meibomian gland secretions
WO2010141648A2 (en) * 2009-06-05 2010-12-09 Allergan, Inc. Artificial tears and therapeutic uses

Also Published As

Publication number Publication date
CN108969482A (zh) 2018-12-11
HK1203057A1 (en) 2015-10-16
US20130197083A1 (en) 2013-08-01
PH12014501296A1 (en) 2014-10-08
US9314528B2 (en) 2016-04-19
MX355216B (es) 2018-04-10
EP4403220A2 (en) 2024-07-24
CL2014001518A1 (es) 2014-10-24
AU2017265181B2 (en) 2019-06-20
ES2896336T3 (es) 2022-02-24
AR089123A1 (es) 2014-07-30
MX2014006804A (es) 2014-09-22
HUE049489T2 (hu) 2020-09-28
PT2787968T (pt) 2020-06-16
JP2015504860A (ja) 2015-02-16
PH12014501296B1 (en) 2023-04-05
JP6142419B2 (ja) 2017-06-07
IN2014CN04809A (enExample) 2015-09-18
EP2787968B1 (en) 2020-03-04
EP2787969B1 (en) 2021-09-29
PT2787969T (pt) 2021-11-09
PL2787969T3 (pl) 2021-12-20
BR112014013820A2 (pt) 2017-06-13
SI2787969T1 (sl) 2021-12-31
PH12021553172A1 (en) 2024-05-27
BR112014013820A8 (pt) 2017-06-13
US20130150324A1 (en) 2013-06-13
EP3981387A1 (en) 2022-04-13
MY173378A (en) 2020-01-21
TW201325633A (zh) 2013-07-01
ZA201404228B (en) 2015-12-23
KR102017922B1 (ko) 2019-09-03
EP4403220A3 (en) 2024-10-23
EP2787968A1 (en) 2014-10-15
RU2018119362A (ru) 2018-11-08
CA2858574C (en) 2017-05-30
RU2014127074A (ru) 2016-02-10
SI2787968T1 (sl) 2020-08-31
IL233008A (en) 2017-07-31
CO6990739A2 (es) 2014-07-10
HUE057140T2 (hu) 2022-04-28
DK2787968T3 (da) 2020-06-02
AU2012347459A1 (en) 2014-07-03
KR20140107383A (ko) 2014-09-04
WO2013086438A1 (en) 2013-06-13
CA2858574A1 (en) 2013-06-13
HK1201458A1 (en) 2015-09-04
RU2018119362A3 (enExample) 2021-09-07
ES2797650T3 (es) 2020-12-03
DK2787969T3 (da) 2021-11-01
AU2017265181A1 (en) 2017-12-14
EP3666257A1 (en) 2020-06-17
SG11201403013VA (en) 2014-07-30
PL2787968T3 (pl) 2020-08-24
TWI652072B (zh) 2019-03-01
IL233008A0 (en) 2014-07-31
WO2013086449A1 (en) 2013-06-13
EP2787969A1 (en) 2014-10-15

Similar Documents

Publication Publication Date Title
Kim et al. Dry eye: why artificial tears are not always the answer
US20240374678A1 (en) Ophthalmic composition for treatment of dry eye disease
Christensen et al. Clinical evaluation of an HP-guar gellable lubricant eye drop for the relief of dryness of the eye
Park et al. Clinical effects and safety of 3% diquafosol ophthalmic solution for patients with dry eye after cataract surgery: a randomized controlled trial
CN104114152A (zh) 用盐敏性乳液体系对人泪液膜进行有效脂质递送
CN111182893A (zh) 包含f6h8的眼用组合物
KR20210080388A (ko) 안구 표면 손상 및 건조 증상 치료를 위한 안약 조성물
WO2014127007A1 (en) Ophthalmic formulation derived from silk protein
US20170239307A1 (en) Composition of doxycycline in liposomes for the prevention, improvement and/or treatment of ocular pathologies
RU2772357C2 (ru) Состав для эффективной доставки липидов в слезную пленку человека с использованием чувствительной к соли эмульсионной системы
WO2025062471A1 (en) Compositions for treatment of dry eye syndrome or corneal wound healing
RU2828769C2 (ru) Офтальмологические композиции для лечения синдрома сухого глаза
CA3076567C (en) Ophthalmic compositions comprising f6h8
HK40114301A (en) Ophthalmic composition for treatment of dry eye disease
US20190224136A1 (en) Artificial tear compositions and methods of use thereof
HK40058504B (en) Ophthalmic composition for treatment of dry eye disease
HK40058504A (en) Ophthalmic composition for treatment of dry eye disease
NZ743307A (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
HK40028751A (en) Ophthalmic compositions comprising f6h8
NZ743307B2 (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
HK1203057B (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
CN105214092A (zh) 重组人白细胞介素-1受体拮抗剂及其组合物及药物用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141022